Schond Greenway

Schond Greenway

No open positions remaining
54 year
Health Technology
Consumer Services
Finance

Profile

Schond L.
Greenway
worked at Halozyme Therapeutics, Inc. as Executive Director-Strategy & IR from 2013 to 2016.
Worked at Mesoblast Ltd. as VP & Global Head-Investor Relations from 2016 to 2021.
Worked at Avalo Therapeutics, Inc. as Chief Financial Officer & Treasurer from 2021 to 2022.
Worked at Definium Therapeutics, Inc. as Chief Financial Officer from 2022 to 2024.
Also held positions at DURECT Corp.
as VP-Investor Relations & Strategic Planning and at Barclays Capital, Inc. as Vice President-Healthcare.
Education includes undergraduate studies at Florida A&M University and an MBA from the University of Virginia Darden School of Business.

Former positions of Schond Greenway

CompaniesPositionEnd
DEFINIUM THERAPEUTICS, INC. Director of Finance/CFO 03/05/2024
AVALO THERAPEUTICS, INC. Director of Finance/CFO 14/02/2022
MESOBLAST LIMITED Investor Relations Contact 01/02/2021
HALOZYME THERAPEUTICS, INC. Investor Relations Contact 01/01/2016
DURECT Public Communications Contact -
See the detail of Schond Greenway's experience

Training of Schond Greenway

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

54

1st degree connections

8

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies8

Health Technology

Health Technology

Finance

Consumer Services

Health Technology

Health Technology

Consumer Services

Health Technology

  1. Stock Market
  2. Insiders
  3. Schond Greenway